MICU1

Across TCGA pan-cancer cohorts, MICU1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MICU1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MICU1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MICU1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where MICU1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.632	0.271	.001	44	view →
LUAD	DFS	Median	All	0.462	0.887	.001	20	view →
GBM	DFS	Median	All	0.321	0.202	.017	7	view →
HNSC	DFS	Median	All	0.493	0.911	.030	7	view →
CCRCC	DFS	Quartile	All	0.573	0.842	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MICU1–PDAC (OS)

Open the PDAC breakdown →